Recommend Maintenance Therapy with Lenalidomide in Multiple Myeloma
Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (ASCT) in MM. This showed improved progression-free survival (PFS) and in some cases, overall survival (OS) [1 –3]. Despite this, use of thalidomide was limited due to toxicity and high rates of therapy discontinuation. Lenalidomide, an analog of thalidomide, had a more favorable toxicity profile making its use in maintenance a potential approach. The use of lenalidomide as a maintenance therapy after ASCT in newly diagnosed MM patients has been investigated in four phase III randomized control studies [4–7].
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Elisabet E. Manasanch Source Type: research
More News: Cancer & Oncology | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants